Journal Article

ER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-κB-dependent manner

Wheeler, Matthew C, Pérez, Antonio Fernández, Mahadevan, Navin R, Zanetti, Maurizio, Rodvold, Jeffrey, Almanza, Gonzalo

2011

Overview

Background Tumor cells adapt to endoplasmic reticulum (ER) stress through a set of conserved intracellular pathways, as part of a process termed the unfolded protein response (UPR). The expression of UPR genes/proteins correlates with increasing progression and poor clinical outcome of several tumor types, including prostate cancer. UPR signaling can activate NF-κB, a master regulator of transcription of pro-inflammatory, tumorigenic cytokines. Previous studies have shown that Lipocalin 2 (Lcn2) is upregulated in several epithelial cancers, including prostate cancer, and recently Lcn2 was implicated as a key mediator of breast cancer progression. Here, we hypothesize that the tumor cell UPR regulates Lcn2 production. Methods We interrogated Lcn2 regulation in murine and human prostate cancer cells undergoing pharmacological and physiological ER stress, and tested UPR and NF-κB dependence by using pharmacological inhibitors of these signaling pathways. Results Induction of ER stress using thapsigargin (Tg), a canonical pharmacologic ER stress inducer, or via glucose deprivation, a physiologic ER stressor present in the tumor microenvironment, upregulates LCN2 production in murine and human prostate cancer cells. Inhibition of the UPR using 4-phenylbutyric acid (PBA) dramatically decreases Lcn2 transcription and translation. Inhibition of NF-κB in prostate cancer cells undergoing Tg-mediated ER stress by BAY 11-7082 abrogates Lcn2 upregulation. Conclusions We conclude that the UPR activates Lcn2 production in prostate cancer cells in an NF-κB-dependent manner. Our results imply that the observed upregulation of Lipocalin 2 in various types of cancer cells may be the direct consequence of concomitant UPR activation, and that the ER stress/Lipocalin 2 axis is a potential new target for intervention in cancer progression.

• Publisher: BioMed Central,BMC
• Subject: Acute-Phase Proteins - biosynthesis / Acute-Phase Proteins - genetics / Adenocarcinoma - genetics / Adenocarcinoma - pathology / Animals / Biomedical and Life Sciences / Biomedicine / Cancer Research / Cell and molecular biology / Cell Line, Tumor - drug effects / Cell Line, Tumor - metabolism / Endoplasmic Reticulum - drug effects / Endoplasmic Reticulum - metabolism / Gene Expression Regulation, Neoplastic - drug effects / Gene Expression Regulation, Neoplastic - genetics / Glucose - pharmacology / Health Promotion and Disease Prevention / Humans / Lipocalin-2 / Lipocalins - biosynthesis / Lipocalins - genetics / Male / Medicine/Public Health / Mice / Neoplasm Proteins - biosynthesis / Neoplasm Proteins - genetics / NF-kappa B - antagonists & inhibitors / NF-kappa B - physiology / Nitriles - pharmacology / Oncogene Proteins - biosynthesis / Oncogene Proteins - genetics / Oncology / Phenylbutyrates - pharmacology / Prostatic Neoplasms - genetics / Prostatic Neoplasms - pathology / Protein Biosynthesis - drug effects / Proto-Oncogene Proteins - biosynthesis / Proto-Oncogene Proteins - genetics / Research Article / Sulfones - pharmacology / Surgical Oncology / Thapsigargin - pharmacology / Transcription, Genetic - drug effects / Tunicamycin - pharmacology / Unfolded Protein Response - drug effects / Unfolded Protein Response - genetics / Up-Regulation - drug effects